TEZ
Sponsors
Vertex Pharmaceuticals Incorporated
Conditions
Cystic Fibrosis
Phase 1
A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis
CompletedNCT03227471
Start: 2017-01-23End: 2018-03-27Updated: 2022-01-18
A Study Evaluating Safety and Pharmacokinetics of VX-440 in Combination With Tezacaftor/Ivacaftor in Healthy Adult Subjects
CompletedNCT03486236
Start: 2016-07-20End: 2016-09-14Updated: 2018-04-03
Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants
RecruitingNCT07283770
Start: 2025-12-09End: 2026-11-19Target: 136Updated: 2026-07-16
Phase 2
A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis
CompletedNCT02951182
Start: 2016-10-31End: 2017-08-31Updated: 2020-08-28
A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis
CompletedNCT03224351
Start: 2017-08-08End: 2018-02-28Updated: 2021-04-22
A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis
CompletedNCT03912233
Start: 2019-04-30End: 2019-12-10Updated: 2023-04-20